BioSpace News Archive

PTC Therapeutics, Inc. announced that on Nov. 29, 2021, the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 49 new employees.

Talis Biomedical Corporation, a company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, announced that the Company’s Board of Directors has granted an inducement award to Brian Blaser, the Company’s newly appointed Chief Executive Officer.

Trophoblast cell surface antigen-2 (Trop-2) is a 35-kDa transmembrane glycoprotein and calcium signal transducer encoded by the TACSTD2 gene, and is structurally related to epithelial cell adhesion molecule (EpCAM).

The healthcare industry is moving with a massive pace towards transformation. With implementation of new technologies and innovative devices the industry is redefining the treatments from inside out.

Point-of-care testing for glucose monitoring is a valuable tool for managing patients with diabetes in the outpatient settings. Coupling of POCT glucose monitoring devices and electronic medical records enable test results to be shared instantly with care providers.

The immunoassay is one of the important analytical techniques based on molecular recognition between antibody and antigen that allows for detection of molecules with high specificity and sensitivity.

Fact.MR – A Market Research and Competitive Intelligence Provider: The market for lithotripsy devices is expected to exceed US$ 2 billion by 2031.

Munich Reinsurance Company’s Canadian life branch (Munich Re) is pleased to announce a partnership with the McGill University Health Centre (MUHC) Foundation to advance cutting-edge cardiovascular disease research.

The global dental 3D printing market size is expected to reach USD 12.46 Billion at a steady CAGR of 26.5% in 2028.

Rising preference for opioid therapy for management of post-operative pain and chronic pain, increasing use of oxycodone to relieve pain and suffering, and growing incidence of chronic pain across the globe are some key factors expected to drive market growth.